Published in Ann Intern Med on April 01, 1998
Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus | NCT01121029
Preferred Treatment of Type 1.5 Diabetes | NCT00194896
Probiotics in Newly Recognized Type 1 Diabetes | NCT03032354
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA (2002) 6.61
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care (2008) 2.87
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care (2012) 2.45
Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care (2012) 2.23
Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J (2008) 2.09
MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes. Nat Med (2014) 1.85
Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci (2013) 1.84
The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia (2014) 1.83
New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care (2009) 1.74
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes (2009) 1.65
Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia (2009) 1.65
Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia (2010) 1.60
The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med (2013) 1.50
Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci (2008) 1.44
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015) 1.36
Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care (2009) 1.32
Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes (2013) 1.31
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia (2012) 1.29
C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev (2009) 1.27
B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care (2013) 1.25
Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2013) 1.21
Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care (2011) 1.20
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes (2013) 1.19
Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr (2008) 1.19
Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes. Diabetes Care (2013) 1.15
The role of immunomodulation therapy in autoimmune diabetes. J Diabetes Sci Technol (2009) 1.15
Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Indian J Endocrinol Metab (2012) 1.13
Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes (2013) 1.11
RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One (2012) 1.09
Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose. Diabetes Care (2013) 1.09
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud (2004) 1.08
T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. Immunol Cell Biol (2016) 1.08
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care (2014) 1.07
The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care (2012) 1.03
Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract (2010) 0.99
Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function. Diabetes Care (2012) 0.96
Immune intervention in type 1 diabetes. Semin Immunol (2011) 0.94
The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther (2013) 0.92
Islet autotransplantation to preserve beta cell mass in selected patients with chronic pancreatitis and diabetes mellitus undergoing total pancreatectomy. Pancreas (2013) 0.91
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes (2008) 0.91
Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding. PLoS One (2013) 0.90
T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol (2011) 0.89
Beta-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care (2009) 0.89
The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes (2012) 0.88
2011 Update: antigen-specific therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes (2011) 0.87
Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care (2014) 0.87
Peripheral blood monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes. Diabetes (2012) 0.87
Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care (2014) 0.87
Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials. Diabetol Metab Syndr (2009) 0.86
Recovery of endocrine function after islet and pancreas transplantation. Curr Diab Rep (2012) 0.85
The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes. Front Immunol (2012) 0.84
Treatment of diabetic rats with encapsulated islets. J Cell Mol Med (2008) 0.84
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One (2011) 0.84
Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care (2013) 0.83
Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control. Diabetes Care (2009) 0.83
Beta-cell destruction and preservation in childhood and adult onset type 1 diabetes. Endocrine (2015) 0.83
Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual beta cell function. Diabetol Metab Syndr (2009) 0.81
Spontaneous complete remission of type 1 diabetes mellitus in an adult - review and case report. J Community Hosp Intern Med Perspect (2015) 0.80
Stem cell-based strategies for the treatment of type 1 diabetes mellitus. Expert Opin Biol Ther (2010) 0.80
One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin. Endocrinol Diabetes Metab Case Rep (2014) 0.80
Characteristics and determinants of partial remission in children with type 1 diabetes using the insulin-dose-adjusted A1C definition. J Diabetes Res (2014) 0.80
Diabetes management: optimizing roles for nurses in insulin initiation. J Multidiscip Healthc (2011) 0.80
Type 1 diabetes: A predictable disease. World J Diabetes (2015) 0.80
Preserved C-peptide levels in overweight or obese compared with underweight children upon diagnosis of type 1 diabetes mellitus. Ann Pediatr Endocrinol Metab (2015) 0.79
Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1. J Gene Med (2010) 0.79
Management of Type 1 Diabetes in Older Adults. Diabetes Spectr (2014) 0.79
Unraveling the contribution of pancreatic beta-cell suicide in autoimmune type 1 diabetes. J Theor Biol (2014) 0.79
New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes. Diabet Med (2008) 0.79
IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS One (2013) 0.78
Diabetes: normal glucose levels should be the goal. Nat Rev Endocrinol (2012) 0.78
Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother (2013) 0.78
Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes. Diabetologia (2014) 0.78
Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol (2002) 0.78
Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual β-cell function 1 year after diagnosis of type 1 diabetes. PLoS One (2013) 0.78
Celebrating 30 years of research accomplishments of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes (2013) 0.78
Pancreatic β Cell Mass Death. Front Pharmacol (2016) 0.77
Adolescent non-adherence reveals a genetic cause for diabetes. Diabet Med (2015) 0.77
Sustained glucagon-like peptide 1 expression from encapsulated transduced cells to treat obese diabetic rats. J Biosci Bioeng (2011) 0.77
The clinical measures associated with C-peptide decline in patients with type 1 diabetes over 15 years. J Korean Med Sci (2013) 0.77
Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes. J Theor Biol (2015) 0.77
Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse. J Clin Invest (2001) 0.77
Anti-inflammatory properties of C-Peptide. Rev Diabet Stud (2009) 0.76
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going? Pharmacol Res (2015) 0.76
Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther (2010) 0.76
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care (2016) 0.76
Deoxyhypusine synthase promotes differentiation and proliferation of T helper type 1 (Th1) cells in autoimmune diabetes. J Biol Chem (2013) 0.76
Possible contribution of taurine to distorted glucagon secretion in intra-islet insulin deficiency: a metabolome analysis using a novel α-cell model of insulin-deficient diabetes. PLoS One (2014) 0.76
Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocr Disord (2012) 0.76
Randomised prospective study for the effect of therapy on residual beta cell function in type-1 diabetes mellitus [ISRCTN70703138]. BMC Endocr Disord (2003) 0.76
Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes. J Diabetes Investig (2010) 0.76
The effectiveness and durability of an early insulin pump therapy in children and adolescents with type 1 diabetes mellitus. Diabetes Technol Ther (2014) 0.75
Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med (2013) 0.75